The expression tendency and prognostic value of PDGFRβ in oral cancer

Lili Wang
Chinese PLA General Hospital

Hongguang Song
Beijing DCN Orthopaedic Hospital

Shiming Yang (fsdgcbc@163.com)
Chinese PLA General Hospital  https://orcid.org/0000-0003-0914-1611

Primary research

Keywords: PDGFRβ, Oral cancer, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-53698/v1

License: Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background Oral cancer is a common malignant tumor in head and neck with poor prognosis. This study aimed to determine the expression tendency and prognostic value of PDGFRβ in oral cancer. Methods The mRNA expression level of PDGFRβ in the oral cancer tissues and adjacent normal tissues of oral cancer patients were detected by quantitative real-time polymerase chain reaction (qRT-PCR). And the association of PDGFRβ expression with clinicopathological characteristic was analyzed via chi-square test. Then we used Kaplan-Meier analysis to analyze the effects of PDGFRβ expression on the overall survival of oral cancer patients. The multivariate cox analysis was used to evaluate its prognostic value. Results The results indicated that the mRNA expression level of PDGFRβ was significantly increased in oral cancer tissues compared with that in the adjacent normal tissue (P < 0.001). And its expression is positively associated with clinical stage, T stage, lymph node metastasis and histological grade. Kaplan-Meier analysis revealed that patients with high expression of PDGFRβ had markedly worse overall survival than those with low expression of PDGFRβ (log rank test, P < 0.05). Additionally, cox regression analysis revealed that the high expression of PDGFRβ was an independent prognostic maker in oral cancer patients. Conclusion PDGFRβ is up-regulated and involved in the development of oral cancer. Moreover, it could be an independent prognostic bio-marker for oral cancer.

Background

Oral cancer is the most common malignant tumor in head and neck, most of which are characterized by invasive growth, invasion of surrounding tissue and easy to occur cervical lymph node metastasis [1]. Approximately 90% of oral neoplasms are oral squamous cell carcinoma (OSCC) [2]. Although surgical resection with chemotherapy and radiotherapy act as the most effective therapeutic method for treatment oral cancer, the prognosis for patients suffering OSCC remain poor [3]. Therefore, it is of important to identify the molecular markers that are associated with oral malignancy; which may further improve the clinical management and therapeutic development.

Platelet-derived growth factor receptors (PDGFRs) are part of the class III receptor tyrosine kinase family, including PDGFRα and PDGFRβ two subtypes [4, 5]. The receptor for PDGF-BB, PDGFRβ, located on chromosome 5q33.1, has an important role in regulating mesenchymal cells development, including pericytes, fibroblasts, and vascular smooth muscle cells [6, 7]. PDGFRα and PDGFRβ are important biological markers of cancer-associated fibroblast (CAFs) that can promote the occurrence, growth, invasion and metastasis of tumor, which are involved in the process of tumor cell proliferation and migration [8–10]. PDGFRβ has been found aberrantly expressed in many diseases and in tumor progression. However, the clinical significance of PDGFRβ in the prognosis of oral cancer was few reported.

In this study, we investigated the expression level of PDGFRβ in clinical oral cancer tissues and adjacent normal tissues. And we also investigated the relationship between PDGFRβ expression and clinicopathological characteristics of patients. Besides, the prognostic value of PDGFRβ was estimated.
Methods

Patients and specimens

A total of 156 patients with oral cancer, who underwent surgery at Chinese PLA General Hospital were included in this study. Among them, there were 74 females and 82 males. They were all histopathologically confirmed and without a prior history of cancer or previous chemo- or radiotherapy. And all the cancer tissues and adjacent normal tissues were extracted from patients and immediately put into liquid nitrogen after surgical resection and then stored at -80 °C until RNA extraction, respectively. The clinicopathology of the cases were summarized in Table 1. A 5-years’ follow-up was conducted and patients who were died from unexpected events or other diseases were excluded from our study.
Table 1
The relationship between *PDGFRβ* expression and clinicopathological features in oral cancer patients

| Characteristics                | No. (n = 156) | PDGFRβ expression | χ² | P values |
|-------------------------------|---------------|-------------------|----|---------|
|                               |               | Low (n = 75)      |     |         |
|                               |               | High (n = 81)     |     |         |
| Age (year)                    |               |                   | 0.605 | 0.437   |
| < 60                          | 82            | 37                | 45  |         |
| ≥ 60                          | 74            | 38                | 36  |         |
| Gender                        |               |                   | 0.256 | 0.613   |
| Male                          | 82            | 41                | 41  |         |
| Female                        | 74            | 34                | 40  |         |
| Clinical stage                |               |                   | 4.394 | 0.036   |
| I-II                          | 80            | 45                | 35  |         |
| III-IV                        | 76            | 30                | 46  |         |
| Histopathological grade       |               |                   | 4.340 | 0.037   |
| G1-G2                         | 78            | 44                | 34  |         |
| G3                            | 78            | 31                | 47  |         |
| T stage                       |               |                   | 6.679 | 0.010   |
| T1-T2                         | 81            | 47                | 34  |         |
| T3-T4                         | 75            | 28                | 47  |         |
| Lymph node metastasis         |               |                   | 6.179 | 0.013   |
| negative                      | 88            | 50                | 38  |         |
| positive                      | 68            | 25                | 43  |         |
| Differentiation               |               |                   | 0.814 | 0.367   |
| Moderate + well               | 92            | 47                | 45  |         |
| poor                          | 64            | 28                | 36  |         |

All the participants provided written, informed consent prior to surgery. The experiment was approved by the Medical Ethics Committee of Chinese PLA General Hospital.
Rna Extraction And Quantitative Real-time Rt-pcr (qrt-pcr)

The PDGFRβ gene was amplified via qRT-PCR. Total RNA was extracted using Trizol reagent (Invitrogen, Carisbad, CA, USA) according to the manufacturer's instructions. Then the first-strand complementary DNA (cDNA) was synthesized using the PrimeScript RT reagent kit (Takara, Dalian, China). QRT-PCR reaction was performed using a SYBR Green Premix Ex Taq (Takara, Dalian China) on the Applied Biosystems 7900 Fast Real-Time PCR system (Applied Biosystems, Foster City, California, USA). β-actin was used as internal control for normalization of data and the expression of PDGFRβ at mRNA level was calculated via the comparative cycle threshold (CT) method. QRT-PCR primer sequences for PDGFRβ were as follows: forward, 5'-GTGGTGAGCACACTGCGTCTG-3' and reverse, 5'-GTAACGTGGCTTCTTCTGCA-3' [11]. Each sample was examined in triplicate.

Statistical analysis

All statistical analyses were performed using SPSS 22.0 statistical software (SPSS, Inc., Chicago, IL, USA). All data were presented as mean ± standard deviation (SD). The associations between protein expression and clinicopathological factors were assessed using the χ² test. The mRNA level of PDGFRβ between tumor and normal groups was compared by Student's t test. The association between PDGFRβ and overall survival was examined using the Kaplan-Meier method and log-rank test. Multivariate analysis was performed to identify the independent risk factor for oral cancer. P values less than 0.05 were regarded as statistically significant.

Results

The expression of PDGFRβ was increased in oral cancer

To test role of PDGFRβ in the progression of oral cancer, we measured the expression levels of PDGFRβ in a total 156 oral cancer tissues and adjacent normal tissues specimens. As shown in Fig. 1, the mRNA expression level of PDGFRβ was significantly higher in oral cancer tissues compared with adjacent normal tissues (P< 0.001).

Relationship between PDGFRβ and clinicopathological characteristics of oral cancer

The correlation between PDGFRβ and clinicopathological features was analyzed via chi-square test. To explore whether PDGFRβ was involved in the development of oral cancer, oral cancer samples were classified into the low expression group (n = 75) and high expression group (n = 81) according to the median expression level of all the samples. As shown in Table 1, the expression of PDGFRβ was positively associated with clinical stage (P= 0.036), T stage (P= 0.010), lymph node metastasis (P= 0.013) and histological grade (P= 0.037). However, there was no significant association was observed between PDGFRβ expression and other parameters including age, gender and differentiation (P > 0.05).

Association of PDGFRβ expression with prognosis in oral cancer patients
To investigate the prognostic role of PDGFRβ in oral cancer, we performed a 5 years’ follow-up. As shown in Fig. 2, our results suggested that patients with high expression of PDGFRβ had a shorter overall survival than those with low expression (log rank test, $P=0.000$). The multivariate analysis using the cox regression analysis adjusted for all variables was performed which manifested that the high expression of PDGFRβ (Table 2, HR = 2.467, 95% CI = 1.340–4.544, $P=0.004$) was an important factor for predicting poor outcome and it might be an independent prognostic bio-marker.

### Table 2

| Variable                  | HR   | 95% CI       | $P$ value |
|---------------------------|------|--------------|-----------|
| PDGFRβ expression         | 2.467| 1.340–4.544  | 0.004     |
| Lymph node metastasis     | 1.859| 1.095–3.156  | 0.022     |
| Differentiation           | 1.813| 1.067–3.082  | 0.028     |

**Discussion**

The occurrence of oral cancer is related to many factors, such as smoking, alcohol use, smokeless tobacco products and HPV infections [12, 13]. The 5-year survival rate of patients with early stage oral cancer ranges from 69–82%, but the 5-year overall survival rate of patients with nodal metastases remain unsatisfactory when compared to the early stage patients [14–16]. The accurate prognostic bio-markers are meaningful for the prediction of the prognosis for oral cancer. Therefore, finding effective prognostic factors is crucial to improve the prognosis and therapy of oral cancer patients.

Recently, many researchers have been devoted to examine specific biological markers with prognosis in head and neck cancer, including oral cancer [17–19]. RUMI YOSHIHAMA et al. indicated that SOX2, KLF4 and brachyury serve important roles in tumor progression, and these transcription factors may thus represent clinically useful prognostic markers for OSCC [20]. Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) was found commonly increased in OSCC and ANP32A protein could act as a potential biomarker for prognosis assessment of oral cancer patients with lymph node metastasis [21].

In this study, we detected the expression of PDGFRβ at mRNA level using qRT-PCR analyses. And PDGFRβ was found to be up-regulated in oral cancer tissues compared to that in adjacent non-cancerous tissues which indicated that it might be a tumor oncogene in oral cancer. Then we further explored the role of PDGFRβ in the development of oral cancer via investigating the relationship between its expression and
clinical factors. The high expression of \textit{PDGFR\beta} was involved in the progression of oral cancer due to its tightly correlation with clinical stage, T stage, lymph node metastasis and histological grade.

\textit{PDGFR\beta} was found high expressed and involved in cancer progression in many types of cancer [22–25]. GONG et al. studied the fusion gene PDGFR\beta-CEV14 in myelodys-plastic and myeloproliferative neoplasms using the methods of FISH and RT-PCR and proven to be of significant value in improving diagnosis, guiding treatment and increasing the cure rate of MDS/MPN patients [11]. Anne S. Tsao et al. evaluated the incidence of PDGFRB gene copy number gain (CNG) by fluorescence in situ hybridization (FISH) and found PDGFRB CNG > 40% of MPM tumor cells is a potential prognostic biomarker for surgery and may identify a unique population of mesothelioma patients [26]. Sayaka Yuzawa et al. suggested the prognostic potential of cancer stroma via PDGF-B signaling and indicated \textit{PDGFR\beta} expression as a reliable prognostic marker and a possible therapeutic target in tumor stroma of pancreatic adenocarcinoma. Accumulated studies had verified \textit{PDGFR\beta} as bio-marker in the prognosis of cancers. So we subsequently evaluated the prognostic value of \textit{PDGFR\beta} in oral cancer.

Kaplan-Meier analysis with the data from follow-up showed that patients with a high \textit{PDGFR\beta} expression had worse overall survival compared to patients with low expression, which suggested that \textit{PDGFR\beta} expression was related to the prognosis of patients with oral cancer. According to cox regression analysis, the result showed high \textit{PDGFR\beta} expression was an independent and significant prognostic factor for oral cancer.

**Conclusion**

In conclusion, \textit{PDGFR\beta} expression is increased in oral cancer patients and its expression is influenced by some clinical factors. The present evidence provides support for \textit{PDGFR\beta} to be a potential prognostic marker. However, it still remains to be further warrant its prognostic utility.

**Declarations:**

**Declarations**

**Ethics approval and consent to participate:** This study was supported by the Ethics Committee of Chinese PLA General Hospital, Beijing and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.

The subjects had been informed the objective. Certainly, written consents were signed by every subject in this study.

**Consent for publication:** The patients provided written informed consent for the publication of any associated data and accompanying images
Availability of data and materials: All data generated or analysed during this study are included in this article.

Competing interests: The authors declare that they have no competing interests.

Funding:

The 63rd batch of grants from China Post-Doctoral Science Fund (2018M633673).

The 11th batch of special grants from China Post-Doctoral Science Fund (2018T111137).

Authors' contributions: L.W., H.S. conceived and designed the experiments, analyzed the data, and wrote the paper. S.Y. performed the experiments. All authors read and approved the final manuscript.

Acknowledgements: Not applicable.

References

1. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C. Neck disease and distant metastases. Oral Oncol. 2003;39(3):207–12.

2. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. Journal of dental research. 2008;87(1):14–32.

3. Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(19):5304–13.

4. Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol. 2002;116(4):744–57.

5. Langerak AW, De Laat PA, Van D Linden-Van Beurden, Delahaye CA, Van Der Kwast M, Hoogsteden TH, Benner HC, Versnel R. MA: Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol. 1996;178(2):151–60.

6. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004;15(4):215–28.

7. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostrom A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009;175(1):334–41.

8. De Wever O, Van Bockstal M, Mareel M, Hendrix A, Bracke M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Sem Cancer Biol. 2014;25:33–46.

9. Calon A, Tauriello DV, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Sem Cancer Biol. 2014;25:15–22.
10. Routray S, Sunkavali A, Bari KA. Carcinoma-associated fibroblasts, its implication in head and neck squamous cell carcinoma: a mini review. Oral Dis. 2014;20(3):246–53.

11. Gong SL, Guo MQ, Tang GS, Zhang CL, Qiu HY, Hu XX, Yang JM. Fusion of platelet-derived growth factor receptor beta to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature. Oncology letters. 2016;11(1):770–4.

12. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer research. 1988;48(11):3282–7.

13. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. cosponsored by the American Society of Preventive Oncology. 2009;18(2):541–50.

14. Contaldo M, Di Napoli A, Pannone G, Franco R, Ionfa F, Feola A, De Rosa A, Santoro A, Sbordone C, Longo F, et al. Prognostic implications of node metastatic features in OSCC: a retrospective study on 121 neck dissections. Oncol Rep. 2013;30(6):2697–704.

15. Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Kreppel M, Zoller J, et al. Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study. Cancer. 2013;119(24):4242–8.

16. Munoz Guerra MF, Naval Gias L, Campo FR, Perez JS. Marginal and segmental mandibulectomy in patients with oral cancer: a statistical analysis of 106 cases. Journal of oral maxillofacial surgery: official journal of the American Association of Oral Maxillofacial Surgeons. 2003;61(11):1289–96.

17. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB. Novel markers for poor prognosis in head and neck cancer. International journal of cancer Journal international du cancer. 2005;113(5):789–97.

18. Qian J, Wenguang X, Zhiyong W, Yuntao Z, Wei H. Hypoxia inducible factor: a potential prognostic biomarker in oral squamous cell carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology Medicine. 2016;37(8):10815–20.

19. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, et al. Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol. 2006;42(9):888–92.

20. Yoshihama R, Yamaguchi K, Imajyo I, Mine M, Hiyake N, Akimoto N, Kobayashi Y, Chigita S, Kumamaru W, Kiyoshima T, et al. Expression levels of SOX2, KLF4 and brachyury transcription factors are associated with metastasis and poor prognosis in oral squamous cell carcinoma. Oncology letters. 2016;11(2):1435–46.

21. Velmurugan BK, Yeh KT, Lee CH, Lin SH, Chin MC, Chiang SL, Wang ZH, Hua CH, Tsai MH, Chang JG, et al. Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) association with lymph node
metastasis predicts poor survival in oral squamous cell carcinoma patients. Oncotarget. 2016;7(10):10879–90.

22. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer. 2005;103(9):1800–9.

23. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003;9(17):6534–44.

24. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003;95(6):458–70.

25. Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest. 1993;69(6):682–9.

26. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, et al. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Annals of diagnostic pathology. 2014;18(3):140–5.

Figures
Figure 1

The mRNA expression of PDGFRβ in oral cancer tissues and normal tissue. The expression level of PDGFRβ in oral cancer tissues was higher than in the adjacent normal specimens (P < 0.001).
Figure 2

Kaplan-Meier analysis for the overall survival of patients with oral cancer. Patients with high PDGFRβ expression had worse overall survival than those low expression (log rank test, P = 0.000)